The global Targeted Protein Degradation Platform market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Targeted Protein Degradation Platform Industry Forecast” looks at past sales and reviews total world Targeted Protein Degradation Platform sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degradation Platform sales for 2024 through 2030.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degradation Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

Segmentation by type:

• PROTAC Platform
• Dual-platform (Molecular Glue and PROTAC)

Segmentation by application:

• Cancer
• Autoimmune Diseases
• Other

Market by region:

• Americas
• APAC
• Europe
• Middle East & Africa

Companies coverage:

• Arvinas
• Kymera Therapeutics
• Plexium
• Nurix
• Amphista
• Cullgen
• Hengrui Pharmaceuticals
• Hinova Pharmaceuticals
• Ranok Therapeutics

Key Questions Addressed in this Report: